Flunixin
| Structural formula | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||
| General | |||||||||||||||||||
| Non-proprietary name | Flunixin | ||||||||||||||||||
| other names |
|
||||||||||||||||||
| Molecular formula | C 14 H 11 F 3 N 2 O 2 | ||||||||||||||||||
| Brief description |
white solid |
||||||||||||||||||
| External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
| Drug information | |||||||||||||||||||
| ATC code | |||||||||||||||||||
| Drug class | |||||||||||||||||||
| Mechanism of action |
Cyclooxygenase inhibitors |
||||||||||||||||||
| properties | |||||||||||||||||||
| Molar mass | 296.25 g · mol -1 | ||||||||||||||||||
| Physical state |
firmly |
||||||||||||||||||
| Melting point |
226-228 ° C |
||||||||||||||||||
| safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | |||||||||||||||||||
Flunixin is a non-opioid analgesic approved exclusively for use in veterinary medicine and is a non- steroidal anti-inflammatory drug (NSAID). It is used as an analgesic for all pain conditions , especially for skeletal diseases and pain in the intestines, and has an anti-inflammatory ( anti-inflammatory ) and antipyretic ( antipyretic ) effect.
chemistry
Flunixin is a derivative of nicotinic acid and belongs to the fenamate group . It is a whitish crystalline powder with a sour taste. It is soluble in water at an alkaline pH . Flunixin is readily soluble in most organic solvents, and at a neutral pH value also in fats.
In veterinary medicine, the salt with meglumine is mainly used, the CAS number for flunixin meglumine is 42461-84-7.
pharmacology
Like all non-steroidal anti-inflammatory drugs, Flunixin works by competitive inhibition of the enzyme cyclooxygenase , which reduces the synthesis of the inflammatory substances prostaglandin H2 and thromboxane . Flunixin also inhibits the release of substance P . In addition, the active ingredient reduces the production of stomach acid .
Flunixin can be used both orally and parenterally ( subcutaneously , intravenously ).
Flunixin is mainly excreted via active secretion in the kidneys . The half-life varies between 1.5 and 8 hours depending on the species. Despite this short half-life, the duration of action is significantly longer at around 12 hours, since significantly higher concentrations are formed in areas of inflammation than in blood plasma .
Contraindications and side effects
Flunixin should not be used in severe kidney dysfunction and severe blood count changes. Some authors advise against using the product during pregnancy, although no teratogenic or mutagenic effects have been demonstrated in laboratory animals . It is not recommended for use in severely dehydrated patients.
Swelling and hardening can occur at the injection site with intramuscular injection, which is why this type of application is not recommended. Occasionally, vomiting and diarrhea may occur.
Trade names
Actiflun, Banamine, Binixin (out of trade), CP-Flunidol (out of trade), Cronyxin, Equibos, Equinixin, Finadyne, Flumeg (out of trade), Flunidol, Fluniximin, Meflosyl, Niglumine, Paraflunixin, Phlogoxin, Resflor, Wellicox
Individual evidence
- ↑ a b c data sheet Flunixin from Sigma-Aldrich , accessed on May 14, 2017 ( PDF ).
- ^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, ISBN 978-0-911910-00-1 , p. 709.
Web links
- Entry on Flunixin at Vetpharm, accessed on July 29, 2012.
